TriNetX has achieved a significant milestone by becoming the most cited electronic health record dataset in peer-reviewed research, as indicated by a recent analysis of PubMed data through August 27, 2025. The Cambridge-based company recorded over 2,000 citations in scientific literature, demonstrating a remarkable growth rate of nearly 80% year-over-year. This positions TriNetX far ahead of its nearest competitor, which garnered just 149 citations.
The findings reveal that TriNetX’s data is increasingly relied upon by clinical researchers, public health agencies, and healthcare organizations around the globe. Citations have surged from only 96 in 2021 to 707 in 2024, with a substantial 952 citations already noted in the first eight months of 2025. At this trajectory, TriNetX is on pace to exceed 1,000 citations within a single year for the first time.
Growing Trust in Real-World Evidence
Dr. Jeffrey Brown, Chief Scientific Officer at TriNetX, emphasized the importance of trust in data used for research. “Researchers need confidence that the data they use will stand up to peer review and drive meaningful insights,” he stated. He further noted that the surge in citations reflects both the quality of TriNetX’s data and the trust placed in it by the global research community to advance science and improve patient outcomes.
Research utilizing TriNetX data has been published in prestigious medical journals, including Nature Medicine, The Journal of Allergy and Clinical Immunology, and JAMIA Open. Studies leveraging the company’s advanced analytic platform are instrumental in developing standards for how real-world data informs clinical drug and vaccine development, safety and effectiveness evaluations, and overall patient care.
The upward trend in citations is also linked to the rapid expansion of the TriNetX LIVETM network. Between September 2024 and September 2025, both healthcare organizations and patient data on the platform reached unprecedented levels. Notably, growth was robust in emerging regions, with Latin America experiencing a 70% increase and the Asia Pacific region climbing 31%.
Strengthening Global Research Foundations
Steve Kundrot, Chief Operating Officer at TriNetX, remarked on the accelerated growth of their network, stating, “Our network’s accelerated growth mirrors the global interests of our customers and network partners, from drug discovery to trial design, comparative effectiveness, and care delivery.” He highlighted that the onboarding of healthcare organizations and the expansion of patient data are enhancing the influence of real-world evidence across the healthcare landscape.
TriNetX operates the world’s most extensive federated network of real-world data, collaborating with healthcare providers to apply advanced intelligence that accelerates innovation in the healthcare ecosystem. Its self-service platform is compliant with HIPAA, GDPR, and LGPD regulations, ensuring the protection of deidentified and anonymous electronic health record datasets.
As TriNetX continues to grow, it solidifies its position as a pivotal resource for credible research, empowering its global community to improve clinical trial design, streamline operations, and enrich the generation of real-world evidence. For more information about TriNetX, visit their official website or connect with them on LinkedIn.
